ClinicalTrials.gg
Not yet recruitingNCT07723599MAPMyeMSUpdated Jul 23, 2026

Combating Age-related Failure of Myelination in Multiple Sclerosis: An Exploratory Study

An observational study in Multiple Sclerosis, sponsored by University of Washington. Not yet recruiting at 1 site in United States. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by University of Washington · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
14
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Multiple Sclerosis by University of Washington — 7 open to participants now, 7 under way, none of them phase 3. Multiple Sclerosis · University of Washington.

Started
2026
with 3 others
Observational
3 of 28
1 open now
Registered
28th of 28
by date

Among the 28 studies in Multiple Sclerosis by University of Washington, this one is one of 4 that started in 2026, is one of 3 observational ones, and was the 28th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

7 of the 28 studies in Multiple Sclerosis by University of Washington are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Multiple Sclerosis by University of Washington, or all of them as a file.
02

Study summary

This observational, longitudinal study will examine whether physical activity and other potentially modifiable lifestyle factors are associated with changes in myelin, the protective coating around nerve fibers, in older adults with multiple sclerosis (MS). Participants will undergo magnetic resonance imaging (MRI) scans to measure myelin throughout the central nervous system and will wear wrist-worn activity trackers to assess physical activity over time.

Read the detailed description

The primary aim of this study is to explore clinical variables and potentially modifiable risk factors that are associated with improved myelination (both enhanced remyelination and reduced demyelination) in older adults living with multiple sclerosis. The emphasis here will be on discovery and generation of pilot data to support further definitive longitudinal observational studies, and ultimately, clinical trials on behavioral and/or pharmaceutical interventions to prevent demyelination and promote remyelination in people living with MS.

Participants will be categorized based on whether they meet or exceed the current physical activity guidelines of at least 150 minutes per week of moderate-intensity aerobic physical activity, 75 minutes per week of vigorous-intensity aerobic physical activity, or an equivalent combination.

At both baseline and 6 months, MRI and clinical assessments will be obtained, and chart review will be performed. Participants will wear a wrist-worn physical activity monitor and answer monthly questionnaires (assessed via REDCap survey) throughout the study period.

Linear regression will be performed to estimate the effect size of various physical activity variables (step count, sedentary time, and time spent in light/moderate/vigorous physical activity, aerobic capacity and overall strength) with 6-month change in myelination.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • remyelination
  • demyelination
  • physical activity
  • multiple sclerosis
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will include adults age 50-70 (inclusive) with a diagnosis of multiple sclerosis in the Greater Seattle area.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis
  • Independent with ambulation (able to walk 500m without aid)
  • Disease duration >10 years
  • Age 50 to 70 years (inclusive)
  • Be able to read, speak, and understand English

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other neurologic disease that would interfere with interpretation such as stroke, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica (NMO), and sarcoidosis.
  • Inability to complete study procedures (including obtaining MRI at BMIC and using Fitbit connected to smartphone)
  • Currently participating in another clinical trial on remyelination
  • Pregnancy. (Pregnancy status will be asked at screening and before each MRI. Pregnancy testing will not be offered as part of this study.)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
14 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults With Multiple Sclerosis

    Participants with multiple sclerosis, age 50-70 (inclusive) will undergo quantitative MRI assessments, wearable activity monitoring, and questionnaire-based assessments over the study period.

    Other: Observation

Interventions

  • OtherObservation

    No intervention is administered. Participants undergo observational assessments including MRI, wearable activity monitoring, and questionnaires.

06

What researchers measure

Primary outcomes

  1. Quantitative MRI-derived myelin measure

    Change in MRI-derived measures of myelin content within the central nervous system. Specifically, the investigators will use macromolecular proton fraction (MPF), a quantitative MRI parameter which describes the magnetization transfer effect and defined as the relative amount of protons bound to biological macromolecules with restricted molecular motion.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Total step count

    Total step count will measured using wrist-worn activity tracker.

    Time frame: Continuously collected during the 6-month study period

  2. Self-reported physical activity

    Physical activity will be measured with the International Physical Activity Questionnaire-Short Form (IPAQ-SF). This questionnaire will ask participants about their moderate and vigorous physical activity and time spent walking, to give a total sum score of Metabolic Equivalent of Task (MET). Higher calculated (MET) scores indicate greater physical activity.

    Time frame: Baseline and monthly for the 6-month study period

  3. Multiple Sclerosis Functional Composite (MSFC)

    The MSFC assesses walking function, hand function, and cognitive function and gives a composite score.

    Time frame: baseline and 6 months

  4. Low Contrast Letter Acuity

    The LCLA assesses visual function

    Time frame: Baseline and 6 months

  5. Time spent in moderate-to-vigorous physical activity (MVPA)

    MVPA will be measured via wrist-worn physical activity monitor

    Time frame: Throughout the 6-month period

  6. Sedentary Time

    Sedentary Time will be measured via wrist-worn fitness tracker

    Time frame: Throughout the 6-month period

  7. Self-reported sedentary time

    Self-reported sedentary time will be measured with the International Physical Activity Questionnaire-Short Form (IPAQ-SF). This questionnaire will ask participants about their time spent sitting over the past 7 days, as an estimate of sedentary time.

    Time frame: Baseline and monthly throughout the 6-month period

Other outcomes

  1. Physical Function

    Physical function will be measured using the PROMIS Physical Function-MS 15a. This self-report questionnaire assesses participants' physical functioning and ability to perform everyday activities.

    Time frame: Baseline and 6 months

  2. Diet Quality

    Diet will be measured using the Dietary Screener Questionnaire (DSQ), a self-report questionnaire that assesses the frequency of consumption of selected foods and beverages during the previous month to estimate intake of key dietary components, including fruits, vegetables, whole grains, dairy products, fiber, and added sugars. The outcome measure will be the total DSQ-derived diet quality score.

    Time frame: Baseline and monthly for the 6-month study period.

  3. Sleep Quality

    Sleep quality will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form 8a, version 1.0. Responses from each item will be summed to form a total raw score ranging from 8-40. Higher scores indicate higher self-reported levels of sleep disturbance.

    Time frame: Baseline and monthly for the 6-month study period.

  4. Stress

    Stress will be measured using the Perceived Stress Scale, a 10-item self-report questionnaire that measures the degree to which situations in an individual's life are appraised as stressful during the previous month. Higher scores indicate greater perceived stress. Raw scores range from 0 to 40 and use reverse scoring for some items.

    Time frame: Baseline and monthly for the 6-month study period.

  5. Depressive Symptom Severity

    This outcome will be measured using the Patient Health Questionnaire- 8 (PHQ-8), a 8-item self-report measure that assesses the frequency and severity of depressive symptoms experienced during the previous 2 weeks. Higher scores indicate greater depressive symptom burden.

    Time frame: Baseline and monthly for the 6-month study period.

  6. Fatigue Severity

    Fatigue will be measured using the Fatigue Severity Scale, a 9-item self-report questionnaire that evaluates the severity of fatigue and its impact on daily activities, work, family, and social functioning. Higher scores indicate greater fatigue severity.

    Time frame: Baseline and monthly for the 6-month study period.

  7. Alcohol Use

    This will be measured via the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C), a 3-item screening measure that assesses alcohol consumption patterns, including drinking frequency, quantity, and frequency of heavy drinking episodes. Higher scores indicate greater alcohol use and risk for hazardous drinking.

    Time frame: Baseline and monthly for the 6-month study period.

  8. Cannabis Use

    This information will be collected through an adapted version of the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU), a self-report measure that assesses cannabis use history and patterns, including age of initiation, frequency of use, quantity consumed, and methods of administration.

    Time frame: Baseline and monthly for the 6-month study period.

  9. Tobacco Use

    This information will be collected through a self-developed questionnaire detailing self-reported tobacco and nicotine product use, including current use status, frequency of use, duration of use, and product type.

    Time frame: Baseline and monthly for the 6-month study period.

  10. Comorbidity Burden

    This information will be collected using a self-reported questionnaire of presence of physician-diagnosed medical and psychiatric comorbid conditions. Comorbidity burden may be summarized as the total number of reported comorbidities.

    Time frame: Baseline and 6 months

07

Study locations

1 site
  • Multiple Sclerosis Center at UW Medical Center - Northwest
    Seattle, Washington 98133, United States
    • Susan R Robles, BS · Contactmsstudy@uw.edu · 206-598-0501
    • Sarah B Simmons, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Study data may be shared in de-identified form with outside researchers and collaborators as requested and deemed acceptable by study investigators.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jun 2027, 10 months later.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 10 months is below that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 23, 2026
StartEst.
Aug 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07723599
Responsible party
Sarah Simmons, MD, PhD (Assistant Professor, Rehabilitation Medicine, University of Washington) — Principal investigator
First posted
Jul 23, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

Susan R Robles, BS
Contact
msstudy@uw.edu
206-598-0501

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion